Background {#sec1_1}
==========

Impaired fine motor skills and tremor are common in Parkinson\'s disease (PD). It is commonly accepted that the origin of the tremor is in the central nervous system, although the exact pathophysiological mechanisms leading to Parkinsonian tremor are still discussed. Several hypotheses regarding the origin of tremor have been proposed in the literature. There seems to be evidence that both the basal ganglia and the cerebello-thalamo-cortical loop are involved in Parkinsonian tremor. Activity in the basal ganglia is primarily affected by dopamine depletion in PD. Recently, a new model, the "dimmer-switch-model," has been proposed. The model combines features of previous hypotheses into a complex model. The dimmer-switch-model explains tremor as resulting from the combined action of two neural circuits: the basal ganglia that trigger tremor-related responses in the cerebello-thalamo-cortical circuit initiate the tremor (switch) and the cerebello-thalamo-cortical circuit produces the tremor and modulates tremor intensity (dimmer). Further, the model suggests that these interactions occur in the motor cortex where the two circuits converge \[[@B1], [@B2]\]. Tremor is associated with rhythmic, bursty, neuronal firing and is clearly visible on surface electromyographic (EMG) recordings \[[@B3]\].

Treatment with bipolar pulsed electromagnetic fields (PEMF) is a non-invasive, rapidly emerging technique. The biophysical effects of PEMF are to depolarize the membrane potential slightly and to induce ion currents in the tissue \[[@B4]\]. The technique (in animals and in vitro) seems to enhance cellular activity and stimulate growth-related responses and regeneration \[[@B4]\]. For example, PEMF has been shown to stimulate nerve growth and attenuate nerve abnormalities, to increase the microvascular blood flow and tissue oxygenation, and to increase capillary density \[[@B5]-[@B8]\]. Thus, a connection between pulsed electromagnetic fields and the physiological response must exist. Treatment with PEMF constitutes a new, potential, non-pharmacological treatment method of PD when applied transcranially to the brain (T-PEMF).

The patient presented in this case report participated in an ongoing study on the effects of long-term treatment with T-PEMF. In this study, we focus on tremor characteristics, muscle activation, and gross motor function in terms of movement speed and functional rate of force development. The reason why this particular patient is presented as a case report was that he produced a detailed written report on signs and symptoms and conducted writing tests during and after the treatment period on his own initiative and blinded to the researchers. The researchers received the patient report and the writing tests after the end of the treatment. These data raised the question whether there were any systematic changes in the activation of the forearm muscles in response to the T-PEMF treatment that could be documented.

Case Report {#sec1_2}
===========

We report on a male patient (age 62 years, body weight 73 kg, height 1.77 m) who had been diagnosed with PD according to the UK Brain Bank criteria 6 years prior to participation. Total score of the Unified Parkinson Disease Rating Scale (UPDRS) was 50, UPDRS-motor was 25, UPDRS-II-handwriting was 3, Hoehn and Yahr stage was 2, and Mini-Mental State Examination score was 30 at baseline. The patient was left-handed, and the left side was most affected. The patient received 1,010 mg/24 h levodopa equivalent dose (Selegeline, Ropinirole, levodopa/benserazide). The patient was medically well-treated, and the medication had not been changed for more than 6 weeks prior to or throughout the T-PEMF intervention period. The patient had no family history of PD. The patient\'s handwriting was characterized by diminution of letter size, a tendency to progressive reduction in size, and lack of fluency, which made his handwriting unreadable at baseline.

The patient was treated with T-PEMF (home-based) in three periods of 8 weeks\' duration separated by a 1-week pause between the treatment periods. Thus, the total intervention period was 26 weeks. Each treatment period included one daily treatment of 30 min duration. No sham treatment was performed. T-PEMF was performed through 7 coils placed in a helmet-like shape, with one coil in the central occipital region, one in the frontal-parietal region (bilateral), and two in the anterior-temporal and posterior-temporal region (bilateral) (Re5 NTS Parkinson Treatment System, Re5, Frederiksberg, Denmark). The coils were connected to an external pulse generator which generated bipolar, squared pulses (amplitude approximately 50 V, duration 3 ms, frequency 55 Hz) to initiate rapid changes in the currents in the coils, which gave rise to a time-dependent, rapidly changing electromagnetic field. The electromagnetic field penetrates through electrically insulated tissue, such as, for example, the skull, and induces a driving force on the charged particles (peak E-field intensity approximately 2.5 mV/cm near the coil) and thereby electrical currents in the brain (Table [1](#T1){ref-type="table"}).

The outcomes in the present case report are forearm muscle activation, handwriting performance, and reported observations. In addition, UPDRS was measured before and after the intervention. All measurements were performed in self-reported on-phase. Surface EMG (MQ-15, Marq Medical, Denmark) was recorded from wrist/finger extensor and wrist flexor muscles (bilaterally). EMG was recorded with the patient seated on a chair (no back support), the shoulders 90 degrees flexed, elbows stretched, arms parallel, palms facing the floor, and an external load of 0.480 kg in each hand (power grip). EMG was measured at baseline (week 0), after 2 periods of T-PEMF treatment (week 17), and on the day after the last T-PEMF treatment (week 27). Measurements of EMG at the three time points during the treatment period were repeated twice for each time point. Each recording lasted 25 s. Handwriting tests, performed during the treatment period, were saved by the patient and shown to the researchers after the end of the treatment. Observations regarding status and changes in motor and non-motor signs and symptoms were reported by the patient and the patient\'s family. The reported observations were given in written form to the researchers after the end of the treatment. EMG results, handwriting tests, and patient observations are presented in Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, and [3](#F3){ref-type="fig"}, respectively. The total UPDRS score was 38, UPDRS-motor was 17, and UPDRS-II-handwriting was 0 after the intervention.

In addition, the patient performed writing tests at 2, 7, 11, and 16 weeks after the treatment. The patient\'s improved writing performance was largely maintained for at least 11 weeks. At week 16 after the intervention, a marked impairment was seen (online suppl. Fig.; for all online suppl. material, see [www.karger.com/doi/10.1159/000492486](http://www.karger.com/doi/10.1159/000492486)).

Discussion {#sec1_3}
==========

The patient had been diagnosed with PD 6 years prior to participation. Handwriting impairment was among the patient\'s first visible signs. Surface EMG was measured on the wrist extensor and flexor muscles during a bilateral, prolonged, low-level, static contraction. A static muscle activation pattern was, therefore, expected bilaterally, in both the extensor and flexor muscles, and with the highest activation level in the extensor muscles. The expected muscle activation pattern was found for the muscles on the right side, which was the patient\'s less affected side (Fig. [1](#F1){ref-type="fig"}). However, on the left side, a spiky EMG pattern with regular burst activity was measured in the extensor muscles and to some extends in the flexor muscles throughout the contractions at baseline. Such an EMG pattern is common in PD and can result in tremor. However, tremor is the mechanical manifestation of involuntary, intermittent muscle activation, and it occurs when the internal torque generated by the muscles exceeds the external torque generated by gravity. Thus, consequently, involuntary EMG burst activity can occur without visible tremor when the internal torque is less than the external torque. However, this type of involuntary muscle activation pattern can certainly disturb fine motor skills, such as, for example, writing ability, due to a lack of force and movement control.

Figure [2](#F2){ref-type="fig"} shows the patient\'s handwriting performance at different time points. Handwriting is a complex motor activity, and dysfunction is a major and common disabling sign of PD, although not included in the diagnosis. In accordance, the lack of readability of his handwriting was a major problem for the patient at baseline. The patient\'s handwriting was significantly improved after the treatment period compared to baseline. This is, letter size was increased, and his writing was much more fluent and certainly readable. Handwriting disability is associated with decreased activity and connectivity in the basal ganglia motor circuit \[[@B9]\]. Furthermore, writing ability and tremor share a common correlate, dopamine, in PD \[[@B10]-[@B12]\]. Therefore, it is hypothesized that long-term treatment with T-PEMF increases the level of dopamine in the brain \[[@B13]\].

EMG measurements at week 17 clearly showed a changed activation pattern of the left forearm muscles compared to baseline. The spiky muscle activation pattern had disappeared, and a pattern corresponding to the right-side EMG was found. The same static activation pattern was found after the third 8-week treatment period. In parallel with this, the three 8-week periods of treatment with T-PEMF improved the readability and the quality of the patient\'s handwriting significantly as shown in Figure [2](#F2){ref-type="fig"}. In accordance, UPDRS-II-handwriting was reduced from 3 to 0 during the treatment period. The major improvement was found after the first two 8-week periods of treatment.

In addition, the patient reported improved fine motor function, less muscle stiffness, and less muscle cramps and tingling in response to the T-PEMF treatment. Furthermore, he experienced less fatigue during day time and became happier (Fig. [3](#F3){ref-type="fig"}). The improved writing ability after the treatment lasted approximately 3 months, indicating a long-term effect.

The present T-PEMF treatment differs significantly from rTMS regarding number of stimulation sites, intensity, frequency, stimuli per session, number of sessions, duration, and location (Table [1](#T1){ref-type="table"}) \[[@B14], [@B15]\]. Thus, T-PEMF induces a high number of weak, pulsating, electric fields in the brain tissue. The electric field is strong enough to cause protein activation but weaker than the limit for eliciting action potentials of brain cells and for opening voltage-dependent Na^+^ channels \[[@B4]\].

In conclusion, it seems likely that the improved motor control, e.g., writing ability, is associated with the present normalization of forearm muscle activation and that this is an effect of long-term treatment with T-PEMF. The presented results should be considered as preliminary, and the effects of T-PEMF should be studied in large-scale, controlled studies to elucidate the therapeutic potential of the new technique.
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![EMG findings during a standardized, low-level, isometric contraction. Surface EMG recorded from the forearm extensor and flexor muscles. 0, at baseline; 17, after two 8-week periods with T-PEMF treatment; 27, after three 8-week periods with T-PEMF treatment.](crn-0010-0242-g01){#F1}

![Handwriting performed before, during, and after the treatment with T-PEMF. **a** Micrographia before the initiation of the treatment. **b** Handwriting test performed after the first two treatment periods. Letter size has increased significantly. **c** Handwriting test performed after the end of the treatment. The patient\'s handwriting is now normalized.](crn-0010-0242-g02){#F2}
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###### 

Characteristics of the presented T-PEMF stimulation method versus typical high- and low-frequency rTMS \[4, 14, 15\]

                       T-PEMF                                                   High-frequency rTMS                            Low-frequency rTMS
  -------------------- -------------------------------------------------------- ---------------------------------------------- ----------------------------------------------
  Sites, *n*           7                                                        1 (or 2)                                       1 (or 2)
  Brain target         large                                                    small                                          small
  Coil                 circular                                                 circular/figure 8                              circular/figure 8
  Intensity            about 6th order of magnitude less than motor threshold   approximately active or rest motor threshold   approximately active or rest motor threshold
  Frequency, Hz        55                                                       5--25 (50)                                     ≤1
  Stimuli/session      99,000                                                   450--3,000                                     60--1,800
  Sessions (total)     168                                                      1--10                                          1--10
  Duration             3 × 8 weeks                                              1 day to 8 weeks                               1 day to 8 weeks
  Treatment location   home                                                     clinic                                         clinic

[^1]: Per Bech has deceased.
